

AD \_\_\_\_\_

GRANT NO: DAMD17-94-J-4306

TITLE: Cell-matrix Interactions in Breast Carcinoma Invasion

PRINCIPAL INVESTIGATOR(S): Filippo G. Giancotti, M.D., Ph.D.

CONTRACTING ORGANIZATION: New York University Medical Center  
New York, New York 10016

REPORT DATE: January 1996

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Frederick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release; distribution unlimited.

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

19960313 087

REPORT DOCUMENTATION PAGE			Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.				
1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE January 1996	3. REPORT TYPE AND DATES COVERED Annual (15 Dec 94 - 14 Dec 95)	
4. TITLE AND SUBTITLE Cell-matrix Interactions in Breast Carcinoma Invasion			5. FUNDING NUMBERS DAMD17-94-J-4306	
6. AUTHOR(S)  Filippo G. Giancotti, M.D., Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) New York University Medical Center New York, New York 10016			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES)  Commander U.S. Army Medical Research and Materiel Command Fort Detrick Frederick, Maryland 21702-5012			10. SPONSORING/MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION/AVAILABILITY STATEMENT  Approved for public release; distribution unlimited			12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 words)  We have used a transgenic mouse model system to investigate the role of integrin defects in breast cancer progression. Transgenic mice carrying an activated form of the N-ras oncogene under the control of the Mammary Tumor Virus Long Terminal Repeat promoter develop mammary carcinomas with a high frequency during the first few months of their life. The $\alpha_6\beta_4$ and, to a minor extent, the $\alpha_2\beta_1$ integrin were found to be upregulated and diffusely distributed at the tumor cell surface in the primary lesions of these mice. These events were accompanied by a loss of laminin staining indicative of defective basement membrane deposition. The $\alpha_3\beta_1$ integrin was diffusely distributed, but not upregulated. Since transfection of N-ras into cultured murine breast epithelial cells did not produce the changes in integrin expression detected <i>in vivo</i> , it is likely that these changes occur as a result of tumor progression independently of a direct action of N-ras. The above described studies indicate that the expression, and possibly the function, of several integrins involved in adhesion to the basement membrane is altered during the <i>in vivo</i> progression of breast cancer in the N-ras transgenic mouse model.				
14. SUBJECT TERMS breast cancer			15. NUMBER OF PAGES 11	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

## GENERAL INSTRUCTIONS FOR COMPLETING SF 298

The Report Documentation Page (RDP) is used in announcing and cataloging reports. It is important that this information be consistent with the rest of the report, particularly the cover and title page. Instructions for filling in each block of the form follow. It is important to *stay within the lines* to meet optical scanning requirements.

### Block 1. Agency Use Only (Leave blank).

**Block 2. Report Date.** Full publication date including day, month, and year, if available (e.g. 1 Jan 88). Must cite at least the year.

**Block 3. Type of Report and Dates Covered.** State whether report is interim, final, etc. If applicable, enter inclusive report dates (e.g. 10 Jun 87 - 30 Jun 88).

**Block 4. Title and Subtitle.** A title is taken from the part of the report that provides the most meaningful and complete information. When a report is prepared in more than one volume, repeat the primary title, add volume number, and include subtitle for the specific volume. On classified documents enter the title classification in parentheses.

**Block 5. Funding Numbers.** To include contract and grant numbers; may include program element number(s), project number(s), task number(s), and work unit number(s). Use the following labels:

C - Contract	PR - Project
G - Grant	TA - Task
PE - Program Element	WU - Work Unit Accession No.

**Block 6. Author(s).** Name(s) of person(s) responsible for writing the report, performing the research, or credited with the content of the report. If editor or compiler, this should follow the name(s).

**Block 7. Performing Organization Name(s) and Address(es).** Self-explanatory.

**Block 8. Performing Organization Report Number.** Enter the unique alphanumeric report number(s) assigned by the organization performing the report.

**Block 9. Sponsoring/Monitoring Agency Name(s) and Address(es).** Self-explanatory.

**Block 10. Sponsoring/Monitoring Agency Report Number.** (If known)

**Block 11. Supplementary Notes.** Enter information not included elsewhere such as: Prepared in cooperation with...; Trans. of...; To be published in.... When a report is revised, include a statement whether the new report supersedes or supplements the older report.

**Block 12a. Distribution/Availability Statement.** Denotes public availability or limitations. Cite any availability to the public. Enter additional limitations or special markings in all capitals (e.g. NOFORN, REL, ITAR).

DOD - See DoDD 5230.24, "Distribution Statements on Technical Documents."

DOE - See authorities.

NASA - See Handbook NHB 2200.2.

NTIS - Leave blank.

### Block 12b. Distribution Code.

DOD - Leave blank.

DOE - Enter DOE distribution categories from the Standard Distribution for Unclassified Scientific and Technical Reports.

NASA - Leave blank.

NTIS - Leave blank.

**Block 13. Abstract.** Include a brief (*Maximum 200 words*) factual summary of the most significant information contained in the report.

**Block 14. Subject Terms.** Keywords or phrases identifying major subjects in the report.

**Block 15. Number of Pages.** Enter the total number of pages.

**Block 16. Price Code.** Enter appropriate price code (*NTIS only*).

**Blocks 17. - 19. Security Classifications.** Self-explanatory. Enter U.S. Security Classification in accordance with U.S. Security Regulations (i.e., UNCLASSIFIED). If form contains classified information, stamp classification on the top and bottom of the page.

**Block 20. Limitation of Abstract.** This block must be completed to assign a limitation to the abstract. Enter either UL (unlimited) or SAR (same as report). An entry in this block is necessary if the abstract is to be limited. If blank, the abstract is assumed to be unlimited.

## FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the US Army.

Where copyrighted material is quoted, permission has been obtained to use such material.

Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

PK In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

PG In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

PG In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

PG In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

FL / J. G. C. W. 1/2/1996  
PI - Signature Date

## **TABLE OF CONTENTS**

<b>Introduction .....</b>	<b>Page 1</b>
<b>Body .....</b>	<b>Page 3</b>
<b>Conclusions .....</b>	<b>Page 5</b>
<b>References .....</b>	<b>Page 5</b>

## INTRODUCTION

Cell-matrix interactions are likely to play an important role in breast tumorigenesis. Most human breast cancers arise from the transformation of ductal epithelial cells (1-3). Normal ductal epithelial cells rest on a basement membrane, to which they adhere tightly (2). The adhesion of normal breast epithelial cells to the basement membrane is thought to be important for the organization of the cytoskeleton and the consequent establishment of polarity. In addition, recent results indicate that normal breast epithelial cells receive signals from the basement membrane and these signals help them maintain a differentiated phenotype (4). When compared to normal cells, breast carcinoma cells show a defective interaction with the basement membrane. First, like most carcinoma cells, they fail to assemble basement membrane components in an organized extracellular matrix, both *in vivo* and *in vitro* (5, 6), and show cytoskeletal defects (7). Second, in contrast to normal breast epithelial cells, carcinoma cells do not arrest their growth when placed in a reconstituted basement membrane gel (6). It is important to understand the molecular basis of these phenomena because they are likely to contribute to the ability of breast carcinoma cells to detach from the original tumor and invade adjacent tissues.

The molecular characterization of integrins provides a unique opportunity to examine the role of cell-matrix interactions in breast cancer. The integrins are a large family of adhesion receptors which bind to extracellular matrix components and, in some cases, to counter-receptors on other cells (8). They consist of two distinct membrane-spanning subunits,  $\alpha$  and  $\beta$ . At present we know of at least 9 homologous  $\beta$  subunits and 15  $\alpha$  subunits which can combine to form 21 receptors with distinct ligand binding specificities. Both the  $\alpha$  and the  $\beta$  subunit (each ca. 140-200 kD m.w.) have a large extracellular portion, a transmembrane segment, and a short cytoplasmic domain. A notable exception is the  $\beta_4$  subunit that has a large cytoplasmic domain. While the extracellular N-termini of  $\alpha$  and  $\beta$  subunits associate to form the ligand binding pocket, the cytoplasmic domains of integrins interact with intracellular molecules.

The binding of integrins to extracellular matrix components promotes cell adhesion or migration, but ligation of integrins also results in intracellular signals which influence proliferation and differentiation (9). While contact with extracellular matrix components is required for the progression of normal cells through the cell cycle, a phenomenon called anchorage dependence, strong adhesion to an organized extracellular matrix seems to be able to limit cell proliferation (10) and promote differentiation (4). The ability of integrins to modulate gene expression may help to explain the effects that the extracellular matrix has on proliferation and differentiation. The mechanisms by which integrins affect gene regulation are not completely understood, but likely depend on the ability of the cytoplasmic domains of integrins to interact both with the cytoskeleton (11) and with signaling molecules, such as Focal Adhesion Kinase (FAK) (12).



Neoplastic cells are characterized by a number of adhesion abnormalities which may explain their ability to grow independently of the positive and negative control signals originating from the extracellular matrix (13). Virally transformed fibroblasts have a more rounded morphology in culture than their non-transformed counterparts. In addition, they often lack a cell surface fibronectin-containing pericellular matrix (14). The defective fibronectin matrix of transformed fibroblasts may only partially be attributed to either decreased biosynthesis or increased proteolytic degradation of fibronectin, since the fibronectin secreted by transformed cells is regularly incorporated in the extracellular matrix by normal cells (15). This suggests that transformed cells can not retain at their surface the fibronectin they produce, perhaps because of a defect in the integrin receptors. Several observations indicate that the expression and function of integrins are altered in neoplastic fibroblasts. While in normal fibroblasts the  $\beta_1$  integrins, which include the  $\alpha_5\beta_1$  fibronectin receptor, are clustered in focal adhesions (16-18), transformed fibroblasts lack such structures and their  $\beta_1$  integrins are found diffusely distributed over the cell surface (18, 19). In addition, in fibroblasts transformed by tyrosine kinase oncogenes the  $\beta_1$  subunit is found to be partially phosphorylated on a tyrosine residue (20), a phenomenon which may reduce its ability to interact with the cytoskeleton (21). Finally, the expression of  $\alpha_5\beta_1$  and of another  $\beta_1$  integrin, probably  $\alpha_1\beta_1$ , is suppressed in fibroblasts transformed by oncogenic viruses (22).

We have tested the hypothesis that changes in the level of expression or function of the  $\alpha_5\beta_1$  fibronectin receptor contribute to the adhesive abnormalities of transformed fibroblasts by overexpressing this integrin in Chinese hamster ovary (CHO) cells (10). The CHO cells have a transformed morphology, deposit little fibronectin in their pericellular matrix and are tumorigenic in vivo. As a result of the  $\alpha_5\beta_1$  overexpression, the CHO cells accumulated a fibronectin matrix and became less migratory. These results, which are described in more detail in Preliminary Studies, indicate an inverse correlation between matrix assembly of fibronectin and cell migration and suggest that the loss of fibronectin matrix and the increased invasive ability of transformed fibroblasts can be both brought about by a reduced expression or function of  $\alpha_5\beta_1$ . Interestingly, the CHO cells overexpressing  $\alpha_5\beta_1$  were also found to be more anchorage dependent than the controls and were not able to form subcutaneous tumors in nude mice. K562 leukemia cells selected for high level expression of  $\alpha_5\beta_1$  show a similar normalization of growth properties (23). Conversely, CHO cells selected for their low levels of  $\alpha_5\beta_1$  expression are more tumorigenic than unselected cells (24). Thus, it appears that changes in the level of expression or activity of certain integrins may not only be responsible for the adhesive defects of neoplastic cells but may also contribute to their unregulated growth. Taken together, these observations suggest that the role of integrins in tumorigenesis is twofold: first, integrins mediate stable adhesion or migration onto extracellular matrix components and changes in their level of expression and function may, therefore, contribute to

tumor invasion. Second, integrins transmit signals from the extracellular matrix to the cell interior and these signals affect cellular growth and differentiation. Therefore changes in integrins may contribute to the unrestrained growth and lack of differentiation of neoplastic cells.

Although the adhesive phenotype of breast carcinoma cells is less well known than that of neoplastic fibroblasts, certain rules learned from the analysis of virally transformed fibroblasts seem to also apply to these cells. For example, breast carcinoma cells fail to assemble basement membrane components in an organized extracellular matrix (5, 6) and show enhanced ability to grow when confronted with a reconstituted basement membrane gel (6). Immunohistochemical studies have indicated that the  $\alpha_2\beta_1$  collagen/laminin receptor, the  $\alpha_5\beta_1$  fibronectin receptor and the  $\alpha_6\beta_4$  integrin, a receptor for various forms of laminin (unpublished results of E. Ruoslahti's and A. Sonnenberg's laboratories), are greatly reduced in human carcinomas of the breast (25-27). In addition, while integrins are generally polarized at the basal or baso-lateral surface in normal breast epithelium, the residual integrins expressed in breast carcinoma cells are diffusely distributed over the cell surface (25-27). It is our hypothesis that these phenomena contribute to the ability of breast carcinoma cells to detach from the original tumor and invade the adjacent tissues.

## BODY

We have focused on establishing a transgenic mouse model system in which to investigate the role of integrin defects in breast cancer progression. To this end, we have examined transgenic mice carrying either an activated or a normal form of the *N-ras* oncogene under the control of the Mammary Tumor Virus Long Terminal Repeat (MMTV-LTR) promoter. These mice, similarly to mice carrying activated forms of the *H-ras* or *neu* oncogenes, develop mammary carcinomas with a high frequency during the first few months of their life (28, 29, 30; R. Manges & A. Pellicer, Department of Pathology, N.Y.U. School of Medicine, unpublished results). The tumors which develop often consist of areas of different level of histological differentiation and thus can provide an insight to the process of primary breast tumor progression.

### A) Immunohistochemical Analysis of Integrin Expression in Normal Murine Breast Tissue and Breast Tumors from a Point-Mutated N-ras Transgenic Mouse Line.

Tissue from normal murine lactating and *N-ras* oncogenic breast tumors were immediately embedded in OCT and frozen on dry ice and then stored at  $-80^{\circ}\text{C}$ . Sections,  $7\text{ }\mu\text{m}$ , were cut on a cryostat and placed on TES treated slides. The slides were briefly air-dried and then desiccated over night at  $4^{\circ}\text{C}$ . The sections were then fixed in ice cold acetone for 10 minutes and then allowed to air dry. H&E staining or immunohistochemical staining was then performed. For immunohistochemical staining, the sections were hydrated in PBS for 20 minutes at



room temperature. The sections were then blocked with PBS/10% normal goat serum for 1 hour in a humidified chamber. The sections were then incubated with the primary antibody solution (anti-integrin antibody in PBS-3% BSA) over night in a humidified chamber at 4<sup>0</sup> C. The slides were washed 3 times in PBS. For double labeling, an anti-laminin antibody solution, also in PBS-3% BSA, was applied for 1 hour at room temperature. Following washes with PBS, secondary antibody solutions with fluorescent-labeled antibodies were then applied for 1 hour each at room temperature. The slides were then mounted and examined by fluorescent microscopy.

Normal murine breast demonstrated laminin staining along the basement membranes of both inter- and intra-lobular ducts as well as those of alveoli. The  $\alpha_6$ ,  $\beta_4$  and  $\beta_1$  subunit were found to colocalize with laminin at the basement membrane junction. The  $\alpha_3$  subunit staining was predominant along the basement membrane of the ducts with less prominent alveolar basal staining. The  $\alpha_2$  subunit staining was similar to that for  $\alpha_3$  but less intense. There was no significant staining above background levels in the ducts for either  $\alpha_5$  or  $\alpha_v$ . Discontinuous  $\alpha_v$  staining could be detected at the myoepithelial basement membrane.

Oncogenic ras murine breast tumors displayed a significant loss of laminin staining. The  $\alpha_6$  and  $\beta_4$  subunits were over-expressed, but lacked polarization; some basal staining could be seen in better differentiated tumor areas. The  $\beta_1$  staining was similarly no longer polarized, but it was not upregulated. The  $\alpha_2$  and  $\alpha_3$  subunits were also diffusely expressed in the tumors with an apparent increased intensity of  $\alpha_2$  staining. The  $\alpha_5$  and  $\alpha_v$  subunits were not expressed in the tumors.

#### B) Effect of Ras on Integrin Expression in a Murine Breast Cell Line.

To determine if the changes in integrin expression *in vivo* were a direct result of ras or due to other genetic changes which occur during tumor progression, the effect of the expression of the N-ras oncogene on integrin expression in abnormal murine breast cell line was investigated. The heterogeneous murine breast cell line NMuNg was dilutionally cloned to isolate an epithelial cell line with an integrin repertoire similar to that of normal breast epithelium. The dilutional clone was stably transfected with a cDNA encoding the N-ras oncogene and the neomycin resistance selection marker. Control cell lines were transfected with the neomycin resistance gene only. Positive clones expressing high levels of N-ras were selected after soft agar subcloning.

Cell surface labeling and immunoprecipitation analysis indicated that the breast epithelial cell lines acutely transformed by N-ras expressed an integrin repertoire indistinguishable from that of control untransformed cell lines. Moreover the level of expression of individual integrin subunits in N-ras expressing cell lines was unchanged as compared to the controls.

## CONCLUSIONS

The above described studies indicate that the expression, and possibly the function, of several integrins involved in adhesion to the basement membrane is altered during the *in vivo* progression of breast cancer in the N-ras transgenic mouse model. The  $\alpha_6\beta_4$  and, to a minor extent, the  $\alpha_2\beta_1$  integrin are upregulated and diffusely distributed at the tumor cell surface in the primary lesions. These events are accompanied by a loss of laminin staining indicative of defective basement membrane deposition. The  $\alpha_3\beta_1$  integrin is diffusely distributed, but not upregulated. Since transfection of N-ras into cultured murine breast epithelial cells does not produce the changes in integrin expression detected *in vivo*, it is likely that these changes occur as a result of tumor progression independently of a direct action of N-ras.

## REFERENCES

- 1) Wellings, S.R., H.M. Jensen, and R.G. Marcum. 1975. An atlas of subgross pathology of the human breast with special reference to possible precancerous lesions. J. Natl. Cancer Inst. 55:231-273.
- 2) Dairkee, S.H., C. Blayney, H.S. Smith, and A.J. Ackett. 1985. Monoclonal antibody that defines human myoepithelium. Proc. Natl. Acad. Sci. U.S.A. 82:7409-7413.
- 3) Rudland, P.S.. 1987. Stem cells and development of mammary cancers in experimental rats and in humans. Cancer Metastasis Rev. 6:55-83.
- 4) Streuli, C.H., N. Bailey, and M.J. Bissell. 1991. Control of mammary epithelial differentiation: basement membrane induced tissue-specific gene expression in the absence of cell-cell interaction and morphological polarity. J. Cell Biol. 115:1383-1395.
- 5) Dulbecco, R., B. Armstrong, and R. Allen. 1988. Reversion toward an earlier stage of differentiation and loss of polarity during progression of N-methyl-N-nitrosourea induced rat mammary tumors. Proc. Natl. Acad. Sci. U.S.A. 85:9292-9296.
- 6) Petersen, O.W., L. Ronnov-Jessen, A.R. Howlett, and M.J. Bissell. 1992. Interaction with basement membrane serves to rapidly distinguish growth and differentiation pattern of normal and malignant human breast epithelial cells. Proc. Natl. Acad. Sci. U.S.A. 89:9064-9068.
- 7) Trask, D.K., V. Band, D.A. Zajchowski, P. Yawsen, T. Suh, and R. Sager. 1990. Keratins as markers that distinguish normal and tumor-derived mammary epithelial cells. Proc. Natl. Acad. Sci. U.S.A. 87:2319-2323.
- 8) Hynes, R.O..1992. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 69:11-25.
- 9) Juliano, R.L., and S. Haskill. 1993. Signal transduction from the extracellular matrix. J. Cell Biol. 120:577-585.
- 10) Giancotti, F.G., and E. Ruoslahti. 1990. Elevated levels of the  $\alpha_5\beta_1$  fibronectin receptor suppress the transformed phenotype of Chinese hamster ovary cells. Cell 60:849-859.

- 11) Burridge, K., K. Fath, T. Kelly, G. Nuckolls, and C. Turner. 1988. Focal adhesions: transmembrane junctions between the extracellular matrix and the cytoskeleton. *Ann. Rev. Cell. Biol.* 4: 487-525.
- 12) Burridge, K., L.A. Petch, and L.H. Romer. 1992. Signals from focal adhesions. *Current Biol.* 10:537-539.
- 13) Ruoslahti, E., and F.G. Giancotti. 1989. Integrins in tumor dissemination. *Cancer Cells* 1:119-126.
- 14) Ruoslahti, E.. 1984. Fibronectin in cell adhesion and invasion. *Cancer Metastasis Rev.* 3:34-51.
- 15) Hayman, E.G., E. Engvall, and E. Ruoslahti. 1981. Concomitant loss of fibronectin and laminin from transformed rat kidney cells. *J. Cell Biol.* 88:352-357.
- 16) Chen, W.T., E. Hasegawa, T. Hasegawa, C. Weinstock, and K.M. Yamada. 1985. Development of cell surface linkage complexes in cultured fibroblasts. *J. Cell Biol.* 100: 1103-1114.
- 17) Damsky, C.H., K.A. Knudsen, D. Bradley, C.A. Buck, and A.F. Horowitz. 1985. Distribution of the cell substratum attachment (CSAT) antigen on myogenic and fibroblastic cells in culture. *J. Cell Biol.* 100: 1528-1539.
- 18) Giancotti, F.G., P.M. Comoglio, and G. Tarone. 1986. A 135,000 molecular weight plasma membrane glycoprotein involved in fibronectin-mediated cell adhesion. Immunofluorescence localization in normal and RSV-transformed fibroblasts. *Exp. Cell Res.* 163:47-62.
- 19) Chen, W.-T., J. Wang, T. Hasegawa, S.S. Yamada, and K.M. Yamada. 1986. Regulation of fibronectin receptor distribution by transformation, exogenous fibronectin, and synthetic peptides. *J. Cell Biol.* 103:1649-1661.
- 20) Hirst, R., A.F. Horwitz, C.A. Buck, and L. Rohrschneider. 1986. Phosphorylation of the fibronectin receptor complex in cells transformed by oncogenes that encode tyrosine kinases. *Proc. Natl. Acad. Sci. U.S.A.* 83:6470-6474.
- 21) Tapley, P., A.F. Horwitz, C.A. Buck, K. Duggan, and L. Rohrschneider. 1989. Integrins isolated from RSV-transformed chicken embryo fibroblasts. *Oncogene* 4:325-333.
- 22) Plantefaber, L.C., and R.O. Hynes. 1989. Changes in integrin receptors on oncogenically transformed cells. *Cell* 56:281-290.
- 23) Symington, B.E.. 1990. Fibronectin receptor overexpression and loss of transformed phenotype in a stable variant of the K562 cell line. *Cell Regul.* 1:637-648.
- 24) Schreiner, C.L., M. Fisher, S. Hussein, and R.L. Juliano. 1991. Increased tumorigenicity of fibronectin receptor deficient Chinese hamster ovary cell variants. *Cancer Res.* 51:1738-1740.
- 25) Zutter, M.M., G. Mazoujian, and S.A. Santoro. 1990. Decreased expression of integrin adhesive protein receptors in adenocarcinoma of the breast. *Am. J. Pathol.* 137:863-870.
- 26) Koukoulis, G.K., E. Virtanen, M. Korhonen, L. Laitinen, V. Quaranta, and V.E. Gould. 1991. Immunohistochemical localization of integrins in the normal, hyperplastic, and neoplastic breast. *Am. J. Pathol.* 139:787-799.

- 27) Natali, P.G., M.R. Nicotra, C. Botti, M. Mottolese, A. Bigotti, and O. Segatto. 1992. Changes in expression of  $\alpha_6\beta_4$  integrin heterodimer in primary and metastatic breast cancer. *Br. J. Cancer* 66:318-322.
- 28) Manges, R., E. Seidman, G.W. Gordon, and A. Pellicer. 1992. Over-expression of the *N-ras* protooncogene, not somatic mutational activation associated with malignant tumors in transgenic mice. *Oncogene* 7:2073-2076.
- 29) Sinn, E., W.J. Muller, P.K. Pattengale, I. Tepler, R. Wallace, and P. Leder. 1987. Coexpression of MMTV/*v-H-ras* and MMTV/*c-myc* genes in transgenic mice: synergistic action of oncogenes *in vivo*. *Cell* 49:465-475.
- 30) Muller, W.J., E. Sinn, P.K. Pattengale, R. Wallace, and P. Leder. 1988. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated *c-neu* oncogene. *Cell* 54:105-115.